Oncology Institute Stock Today
| TOI Stock | USD 0.15 0.01 6.25% |
Performance0 of 100
| Odds Of DistressOver 53
|
Oncology Institute is trading at 0.15 as of the 25th of November 2024. This is a 6.25 percent decrease since the beginning of the trading day. The stock's open price was 0.16. Oncology Institute has 53 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Oncology Institute are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 15th of November 2021 | Category Healthcare | Classification Health Care |
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California. Oncology Institute operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. The company has 75.56 M outstanding shares of which 247.97 K shares are at this time shorted by investors with about 3.38 days to cover. More on Oncology Institute
Moving together with Oncology Stock
Moving against Oncology Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Oncology Stock Highlights
| Thematic Idea | Healthcare (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [TOI, TRIOIL RES-A - Frankfurt Stock Exchang] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Healthcare, Health Care, Health Care Equipment & Supplies, Medical Care Facilities, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOncology Institute can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Oncology Institute's financial leverage. It provides some insight into what part of Oncology Institute's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Oncology Institute (TOI) is traded on NASDAQ Exchange in USA. It is located in 18000 Studebaker Road, Cerritos, CA, United States, 90703 and employs 800 people. Oncology Institute is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 11.65 M. Oncology Institute runs under Health Care Equipment & Supplies sector within Health Care industry. The entity has 75.56 M outstanding shares of which 247.97 K shares are at this time shorted by investors with about 3.38 days to cover.
Oncology Institute has about 64.21 M in cash with (36.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Oncology Institute Probability Of Bankruptcy
Ownership AllocationOncology Institute owns a total of 75.56 Million outstanding shares. 30% of Oncology Institute outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Oncology Ownership Details
Oncology Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Freegulliver, Llc | 2024-09-30 | 188.2 K | |
| Renaissance Technologies Corp | 2024-09-30 | 170 K | |
| Millennium Management Llc | 2024-06-30 | 109.2 K | |
| State Street Corp | 2024-06-30 | 101.3 K | |
| Saba Capital Management, Lp | 2024-06-30 | 94.3 K | |
| Citadel Advisors Llc | 2024-09-30 | 91.3 K | |
| Fielder Capital Group Llc | 2024-09-30 | 70.2 K | |
| Northern Trust Corp | 2024-09-30 | 64.9 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 58.7 K | |
| Fmr Inc | 2024-09-30 | 4.7 M | |
| Deerfield Management Co | 2024-09-30 | 3.4 M |
Oncology Institute Historical Income Statement
Oncology Stock Against Markets
Oncology Institute Corporate Management
| FACHE MD | Chief Officer | Profile | |
| Mark Esq | General Counsel | Profile | |
| Rob Carter | Senior Finance | Profile | |
| Bradford Hively | CEO Director | Profile | |
| Rakesh MBA | Director Technology | Profile | |
| Laura Szitar | Chief Officer | Profile | |
| Richard Barasch | Executive Board | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Oncology Institute. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share 4.873 | Quarterly Revenue Growth 0.229 | Return On Assets (0.19) | Return On Equity (1.26) |
The market value of Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.